skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment

Review

(2098) Views  (577) Full article downloads

Authors: Isabelle Deshaies, Jovenel Cherenfant, Niraj J Gusani, et al

Published Date September 2010 Volume 2010:6 Pages 453 - 458
DOI: http://dx.doi.org/10.2147/TCRM.S5634

Isabelle Deshaies1, Jovenel Cherenfant1, Niraj J Gusani1, Yixing Jiang2, Harold A Harvey2, Eric T Kimchi1, Jussuf T Kaifi1, Kevin F Staveley-O’Carroll1
1Program for Liver, Pancreas and Foregut Tumors, Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA; 2Department of Medical Oncology, Penn State College of Medicine, Hershey, Pennsylvania, USA

Abstract: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery with complete removal of the tumor is the primary treatment for resectable GIST and the only chance of cure. However, recurrence after surgery is common. The 2 main prognostic factors are the mitotic activity and the size of the tumor. Tumor rupture is also a risk factor for postoperative recurrence, and extra care should be taken while manipulating this soft and friable tumor. Imatinib mesylate (IM, Gleevec®, Novartis, Basel, Switzerland) is a tyrosine kinase inhibitor and was first studied in the palliative setting for metastatic GIST patients in the year 2000. It is now the cornerstone of metastatic GIST treatment. IM also plays an important role as an adjuvant treatment for resectable GIST and has been shown to increase the recurrence-free survival in phase III studies. However, some points remain to be clarified. Notably, the ideal duration of adjuvant IM after surgery is still unclear. It is also difficult to determine the exact place of surgery in metastatic or recurrent GIST patients in the IM era. A multidisciplinary approach is, therefore, mandatory to offer GIST patients the best treatment available.

Keywords: Gleevec, adjuvant, neoadjuvant, metastasis, sunitinib

 








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Role of osteogenic protein-1/bone morphogenetic protein-7 in spinal fusion
New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tablets
Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study
Reference values of hematological indices of infants, children, and adolescents in Port Harcourt, Nigeria
Effects of recombinant growth hormone replacement and physical rehabilitation in recovery of gross motor function in children with cerebral palsy
Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells
High-energy ball milling technique for ZnO nanoparticles as antibacterial material
Cyclophilin A cooperates with MIP-2 to augment neutrophil migration
Experiences and perspectives on the GIST patient journey